Latest News

Choosing Appropriate Patients for Dual Immunotherapy/Chemotherapy in NSCLC
Choosing Appropriate Patients for Dual Immunotherapy/Chemotherapy in NSCLC

September 18th 2023

During a Targeted Oncology™ Case-Based Roundtable™ event, Sandip P. Patel, MD, discussed which patients with non–small cell lung cancer should receive immunotherapy-containing regimens. This is the second of 2 articles based on this event.

Nivolumab/Ipilimumab Continues to Show OS Benefit in NSCLC at 6 Years
Nivolumab/Ipilimumab Continues to Show OS Benefit in NSCLC at 6 Years

September 18th 2023

Atezolizumab Combo Shows Potential in Advanced NSCLC With Brain Metastases
Atezolizumab Combo Shows Potential in Advanced NSCLC With Brain Metastases

September 18th 2023

Significant Benefit Shown with Perioperative Durvalumab/Chemo in Resectable NSCLC
Significant Benefit Shown with Perioperative Durvalumab/Chemo in Resectable NSCLC

September 16th 2023

FLAURA Data Provides Insight on Sequencing Therapy for EGFR+ NSCLC
FLAURA Data Provides Insight on Sequencing Therapy for EGFR+ NSCLC

September 14th 2023

Video Series
Video Interviews
Podcasts

More News